TITLE

Jentadueto: A New Oral Antihyperglycemic Combination Therapy for Patients with Type 2 Diabetes

AUTHOR(S)
Kuznar, Wayne
PUB. DATE
April 2013
SOURCE
American Health & Drug Benefits;Apr2013, Vol. 6 Issue 3, p52
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The article discusses jentadueto as a new oral combination of antihyperglycemic therapy for type 2 diabetes patients. Topics include support of the European Association for the Study of Diabetes (EASD) and the American Diabetes Association (ADA) for the use of metformin (glucophage) in patients with type 2 diabetes. It also mentions the Food and Drug Administration (FDA) approval for jentadueto oral tablet with a combination of metformin hydrochloride and linagliptin, its dosing and efficacy.
ACCESSION #
94989906

 

Related Articles

  • TODAY Study: Tackling glycaemic control in adolescents.  // Diabetes Digest;2012, Vol. 11 Issue 3, p139 

    The article discusses a research by Treatment Options for Type 2 Diabetes in Adolescents and Youth (TODAY) group comparing early combined treatment effects with metformin alone on glycaemic control revealing that people with T2D benefit from combination treatment initiated early following diagnosis.

  • Clinical effects of once-weekly exenatide for the treatment of type 2 diabetes mellitus. RYAN, GINA J.; MONIRI, NADER H.; SMILEY, DAWN D. // American Journal of Health-System Pharmacy;7/1/2013, Vol. 70 Issue 13, p1123 

    Purpose. The pharmacology, pharmacokinetics, clinical efficacy, adverse effects, administration, dosage, place in therapy, and cost of extended-release exenatide are reviewed. Summary. Regular-release exenatide has a half-life of 2.4 hours and is administered twice daily. In order to allow for...

  • Dapagliflozin: A Review of its Use in Type 2 Diabetes Mellitus. Plosker, Greg L.; Cheung, B. M.; Cucinotta, D.; Nilsson, P. M.; Penfornis, A.; Scheen, A. J. // Drugs;2012, Vol. 72 Issue 17, p2289 

    Dapagliflozin (Forxiga®) is the first in a novel class of glucose-lowering agents known as sodium-glucose co-transporter-2 (SGLT2) inhibitors and is used in the treatment of patients with type 2 diabetes. By inhibiting the transporter protein SGLT2 in the kidneys, dapagliflozin reduces renal...

  • Long-Term CV Effects of Intensive Glucose Lowering: The ACCORD Study.  // Clinical Cardiology Alert;May2011 Supplement, p1 

    The article reports the Action to Control Cardiovascular Risk in Diabetes (ACCORD) study by H. C. Gerstein and colleagues, which examined the long term effects of intensive glucose lowering or tight control on cardiovascular (CV) outcomes in diabetic patients, and revealed that hypoglycemia is...

  • Long-Term CV Effects of Intensive Glucose Lowering: The ACCORD Study.  // Clinical Oncology Alert; 

    The article reports the action to control cardiovascular risk in diabetes (ACCORD) study by H. C. Gerstein and colleagues, which examined the long term effects of intensive glucose lowering or tight control on cardiovascular (CV) outcomes in diabetic patients, and revealed that hypoglycemia is...

  • DPP-4 inhibitors: Safety and efficacy in treatment of T2D.  // Diabetes Digest;2012, Vol. 11 Issue 3, p143 

    The article presents a brief summary of a study by T. Karagiannis and colleagues to determine the efficacy and safety of dipeptidyl peptidase-4 (DPP-4) inhibitors as compared with other oral hypoglycaemic medications in people with type 2 diabetes.

  • Efficacy of secondline therapies added to metformin in T2D.  // Diabetes Digest;2012, Vol. 11 Issue 3, p143 

    The article discusses a study conducted by S. C. Liu, Y. K. Tu, M. N. Chien and colleagues comparing the efficacy of second-line antidiabetes drugs in people with T2D taking metformin.

  • Alogliptin: A new dipeptidyl peptidase-4 inhibitor for the management of type 2 diabetes mellitus. NDEFO, UCHE ANADU; OKOLI, OKWUCHUKWU; EROWELE, GOLDINA // American Journal of Health-System Pharmacy;1/15/2014, Vol. 71 Issue 2, p103 

    Purpose. The pharmacology, pharmacodynamics, pharmacokinetics, safety, efficacy, and place in therapy of alogliptin and its combinations for managing type 2 diabetes mellitus are reviewed. Summary. Alogliptin is a selective, orally bioavailable inhibitor of the enzymatic activity of dipeptidyl...

  • Replacing Carbohydrates with Nuts in the Diabetic Diet.  // Clinical Cardiology Alert;Nov2011 Clinical Brief, p21 

    The article discusses a study by D. J. Jenkins and colleagues, which shows that replacing carbohydrates with nuts in a diet for type 2 diabetes patients significantly reduced their glycated hemoglobin (A1c) levels.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics